Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants

被引:24
作者
Cadnapaphornchai, Melissa A. [1 ,2 ]
George, Diana M. [1 ]
Masoumi, Amirali [1 ]
McFann, Kim [1 ]
Strain, John D. [3 ]
Schrier, Robert W. [1 ]
机构
[1] Univ Colorado Denver, PKD Res Grp, Dept Med, Aurora, CO 80045 USA
[2] Univ Colorado Denver, Dept Pediat, Aurora, CO USA
[3] Childrens Hosp, Dept Radiol, Aurora, CO USA
关键词
Pediatric; Autosomal dominant polycystic kidney disease; Statin; Renal volume; POLYCYSTIC KIDNEY-DISEASE; ANGIOTENSIN-CONVERTING ENZYME; LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR MAGNETIC-RESONANCE; VASCULAR SMOOTH-MUSCLE; AUTOSOMAL-DOMINANT; BLOOD-PRESSURE; RENAL-FUNCTION; NORMOTENSIVE PATIENTS; CARDIAC-HYPERTROPHY;
D O I
10.1016/j.cct.2011.01.008
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney condition and is associated with important renal and cardiovascular. manifestations in childhood. Renal cystic disease can be documented in some cases as early as in utero. Early intervention is critical if the long-term complications of this condition, including end-stage renal disease, are to be ameliorated. Here we describe our ongoing randomized double-blind placebo-controlled phase III clinical trial to assess the effect of pravastatin treatment on renal and cardiovascular disease progression in 107 children and young adults age 8-22 years with ADPKD who are receiving the angiotensin converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data are provided. Results of this study could markedly impact the standard of care for evaluation and treatment of ADPKD in this population. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:437 / 445
页数:9
相关论文
共 77 条
[1]
Artigao L M, 2000, Aten Primaria, V25, P96
[2]
Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease [J].
Bae, KT ;
Commean, PK ;
Lee, J .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2000, 24 (04) :614-619
[3]
DIFFERENCES IN HORMONAL AND RENAL VASCULAR-RESPONSES BETWEEN NORMOTENSIVE PATIENTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE AND UNAFFECTED FAMILY MEMBERS [J].
BARRETT, BJ ;
FOLEY, R ;
MORGAN, J ;
HEFFERTON, D ;
PARFREY, P .
KIDNEY INTERNATIONAL, 1994, 46 (04) :1118-1123
[4]
HYPERTENSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
BELL, PE ;
HOSSACK, KF ;
GABOW, PA ;
DURR, JA ;
JOHNSON, AM ;
SCHRIER, RW .
KIDNEY INTERNATIONAL, 1988, 34 (05) :683-690
[5]
BERNSTEIN J, 1987, AM J PATHOL, V129, P92
[6]
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].
Bianchi, S ;
Bigazzi, R ;
Caiazza, A ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570
[7]
Brunner HR, 2001, AM J CARDIOL, V87, p3C
[8]
Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD) [J].
Cadnapaphornchai, MA ;
Fick-Brosnahan, GM ;
Duley, I ;
Johnson, AM ;
Strain, JD ;
DeGroff, CG ;
Schrier, RW .
CONTEMPORARY CLINICAL TRIALS, 2005, 26 (02) :211-222
[9]
Cadnapaphornchai MA, 2010, CLIN J AM SOC N 1129
[10]
Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension [J].
Cadnapaphornchai, Melissa A. ;
McFann, Kim ;
Strain, John D. ;
Masoumi, Amirali ;
Schrier, Robert W. .
KIDNEY INTERNATIONAL, 2008, 74 (09) :1192-1196